Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC Pennell NA; Lynch TJ JrOncologist 2009[Apr]; 14 (4): 399-411Multitargeted agents represent the next generation of targeted therapies in solid tumors. The benefits of individually targeting the vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) signaling pathways have been clinically validated in recent years in a number of solid tumor types including non-small cell lung cancer (NSCLC). Given the heterogeneity of this tumor type and potential crosstalk between these key signaling pathways (which are known to play a critical role in tumor growth, metastasis, and angiogenesis), dual inhibition of the VEGFR and EGFR signaling pathways has the potential to offer additional clinical benefits in NSCLC. A number of approaches to inhibiting both VEGFR and EGFR signaling are currently under investigation, including monotherapy with a multitargeted tyrosine kinase inhibitor (e.g., vandetanib, AEE788, XL647, BMS-690514) or a combination of single-targeted therapies (e.g., bevacizumab, cetuximab, erlotinib, gefitinib). Preclinical and early clinical data (phase I and II trials) support combined inhibition of the VEGFR and EGFR pathways in NSCLC. Overall, combined inhibition strategies are well tolerated and have shown promise in early clinical studies. Ongoing phase II and phase III trials will determine the clinical potential of a number of dual inhibition strategies in the treatment of advanced NSCLC.|Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism[MESH]|Clinical Trials as Topic[MESH]|Clinical Trials, Phase I as Topic[MESH]|Clinical Trials, Phase II as Topic[MESH]|Drug Therapy, Combination[MESH]|ErbB Receptors/*antagonists & inhibitors[MESH]|Evidence-Based Medicine[MESH]|Humans[MESH]|Lung Neoplasms/*drug therapy/metabolism[MESH]|Protein Kinase Inhibitors/*therapeutic use[MESH]|Receptors, Vascular Endothelial Growth Factor/*antagonists & inhibitors[MESH]|Signal Transduction/*drug effects[MESH]|Treatment Outcome[MESH]|Vascular Endothelial Growth Factor Receptor-1/antagonists & inhibitors[MESH] |